Pankaj Mohan, Ph.D.
Founder, CEO & Chairman
Dr. Mohan founded Sonnet in 2015 and currently serves as Chief Executive Officer and Chairman. He is also a member of the Board of Directors of Outlook Therapeutics, Inc. which he also founded (formerly known as Oncobiologics). From January 2011 to June 2018, he served as Oncobiologics’ President, Chief Executive Officer and Chairman. Previously, Dr. Mohan served as head of Business Operations and Portfolio Management of Biologics Process and Product Development at Bristol-Myers Squibb Company and as a Director of Bioprocess Engineering at Genentech, Inc. Prior to that Dr. Mohan served as a senior manager at Eli Lilly and Company. From May 1993 to April 1996, Dr. Mohan served as Assistant Professor (Lecturer/Fellow) at the Advanced Centre for Biochemical Engineering, University College London, London, United Kingdom.
Dr. Mohan received a Ph.D. in Biochemical Engineering from the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom, a masters in Financial Management from Middlesex University Business School, London, United Kingdom, an Executive Management Program (AMP) from Fuqua School of Business at Duke University and a Bachelor of Chemical Engineering from the Indian Institute of Technology in Roorkee, India.
Donald J. Griffith, C.P.A.
Chief Financial Officer
Mr. Griffith currently serves as Chief Financial Officer of Sonnet BioTherapeutics. He is also currently a member of the board of directors at Sonnet BioTherapeutics. Previously, Mr. Griffith served as Chief Financial Officer and Secretary at Oncobiologics from May 2011 through September 2015. From May 1991 to May 2011, Mr. Griffith served as a partner at Stolz & Griffith, LLC, a New Jersey accounting firm.
Mr. Griffith is an active member of the New Jersey Society of CPAs and the American Institute of CPAs. Mr. Griffith received an M.B.A. from Fairleigh Dickenson University and a B.B.A. in Business Administration from the City College of New York.
John K. Cini, Ph.D.
Chief Scientific Officer & Co-Founder
Dr. Cini is Chief Scientific Officer and a Co-Founder of Sonnet BioTherapeutics, where he oversees and directs the company’s discovery and development programs. His role includes the oversight of the selection process of cancer and immune oncology targets and proof-of-concept testing.
Prior to joining Sonnet, he was Vice President of Discovery and Development Sciences at Oncobiologics. He has successfully advanced more than 20 novel monoclonal antibody products from discovery to IND. He is the holder of several novel product and formulation patents and applications. He has been directly involved in several successful novel biologics through early discovery research into development and manufacturing through clinical trials and commercialization.
Previous positions include Executive Director at Mederex (acquired by Bristol-Myers Squibb in 2010), lead discovery scientific roles at Johnson & Johnson (Ethicon, OrthoBioTech & Pharmaceutical Research), and Bayer. Dr. Cini’s therapeutic areas of expertise in system biology include oncology, immune-oncology, inflammation, osteoporosis, wound healing, surgical adhesion and cellular aging.
Terence Rugg, M.D.
Chief Medical Officer
Dr. Rugg serves as Sonnet’s Chief Medical Officer in a part-time consulting role. He is an internationally respected oncologist with nearly 30 years experience in the development of oncology drugs at both large and small pharma companies and has been involved in the development of more 30 compounds including at least 12 different classes of anti-cancer drugs.
Prior to joining Sonnet, Dr. Rugg served as Vice President, BioOncology Medical Affairs at Genentech. Prior to Genentech, he was Chief Medical Officer and VP-Development for SGX Pharmaceuticals, Vice President and Head of Oncology/Medical Affairs at sanofi-aventis and Head of Oncology for Aventis Global Medical Affairs. He has also held various positions at Eli Lilly and Company, Zeneca Pharmaceuticals, Ilex Oncology and British Biotech. In recent years, he has served as an independent consultant to the pharmaceutical industry.
Dr. Rugg earned his medical degree from Godfrey Huggins School of Medicine and his undergraduate degree from the University of Rhodesia. He is a Licentiate of the Royal Colleges of Medicine and Surgery, of Edinburgh and Glasgow and earned a Master of Medicine in Clinical Oncology and Radiotherapy at the University of Natal, South Africa.
Chief Technical Officer
Susan Dexter serves as Sonnet’s Chief Technical Officer. She comes to Sonnet with more than twenty-five years in biotechnology science, manufacturing and business development. Susan’s experience includes management of biotechnology contract manufacturing services ranging from process development through commercial manufacturing, and strategic consulting related services. Her prior roles include Managing Director, Latham Biopharm Group; Chief Business Officer at Xcellerex, Inc.; VP of Business Development at The Dow Chemical Company; Assoc. Director of Business Development, Celltech and Lonza.
Ms. Dexter holds a double major with Honors in Immunology and Marketing from American University, Washington, D.C.